Retailer news
Superdrug ‘first to stock’ £99 non-hormonal menopause medication
In Retailer news
Bookmark
Record learning outcomes
Superdrug has said it is the first high street business in the UK to stock Veoza, a non-hormonal medicine aimed at alleviating the symptoms of menopause.
The product, which contains fezolinetant 45mg and targets hot flushes and night sweats, will retail at £99 for a pack of 28, the company said.
The drug is indicated for perimenopausal, menopausal and postmenopausal women aged 45-65 who are not on HRT or hormonal contraception and are suffering from moderate to severe vasomotor symptoms, said Superdrug.
Dr Babak Ashrafi, a GP working for Superdrug Online Doctor, commented: “As a healthcare provider, I am impressed by the positive outcomes observed with Veoza.
“According to the Lancet study, compared with the placebo, fezolinetant 45mg significantly reduced the frequency and severity of vasomotor symptoms at week 4 and week 12. Improvements in frequency and severity of vasomotor symptoms were observed after one week and maintained over two weeks.”
Superdrug healthcare director Ghada Beale said: “We understand the unique challenges faced during menopause and are dedicated to offering accessible, effective and choice-driven solutions.”